Profile: Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

737.85INR
5 Mar 2015
Change (% chg)

Rs13.15 (+1.81%)
Prev Close
Rs724.70
Open
Rs725.00
Day's High
Rs745.80
Day's Low
Rs724.15
Volume
171,618
Avg. Vol
176,947
52-wk High
Rs746.50
52-wk Low
Rs368.70

Search Stocks
Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin acetate injection) for new antifungal for life-threatening fungal infections; Endobloc (ambrisentan tablets); Esomac (esomeprazole tablets); Evocort (formoterol and mometasone rotacaps)-new once-daily asthma controller therapy; Isablac (lactulose and isphaghula husk granules), and Ivabeat (ivabradine tablets) drug for coronary artery disease and chronic heart failure. In July 2013, the Company acquired Cipla Medpro South Africa Limited. In November 2013, the Company’s wholly owned step down subsidiary Meditab Holdings Limited, acquired an additional 14.5% interest in Quality Chemical Industries Limited (QCIL) and now held 51.05% interest in QCIL.

Company Address

Cipla Ltd

Mumbai Central
MUMBAI     400008
P: +9122.23082891
F: +9122.23070013

Company Web Links

Search Stocks